SEGMENT INFORMATION TECHNE CORPORATION AND SUBISIDARIES (in thousands of $'s, except per share data) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ------------------ ------------------- First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 66,534 100% (2,790) Cost of sales 12,901 19% (185) ------- -------- ------- Gross margin 53,633 81% (2,605) Gross margin percentage 80.6% SG&A expense 8,038 12% (802) R&D expense 6,154 10% 244 Amortization expense 240 -- -- Interest income (1,168) (2%) 1,719 Other non-operating ex., net 662 1% (525) ------- -------- ------- 13,926 21% 636 ------- -------- ------- Earnings before income taxes 39,707 60% (3,241) Income taxes 12,935 20% (1,420) ------- -------- ------- 26,772 40% (1,821) ======= ======== ======= Diluted earnings per share .72 Weighted average diluted shares outstanding 37,339 BIOTECHNOLOGY (1) (in thousands of $'s) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ------------------ ------------------- First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 51,696 100% (2,203) Intersegment sales (7,668) 94 ------- ------- 44,028 (2,109) Cost of sales 9,885 19% (362) Intersegment sales (7,598) (137) ------- ------- 2,287 (499) Gross margin 41,741 81% (1,610) Gross margin percentage 80.9% SG&A expense 4,734 9% (407) R&D expense 5,956 12% 239 Amortization expense 240 -- -- Interest, net (771) (1%) 313 Other expense 2 -- 4 ------- -------- ------- 10,161 20% 149 ------- -------- ------- Pretax result 31,580 61% (1,759) ======= ======== ======= (1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc. and R&D China R&D SYSTEMS EUROPE (in thousands of Br. pound's) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ------------------ ------------------- First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 10,881 100% 706 Cost of sales 5,061 47% 801 ------- -------- ------- Gross margin 5,820 53% (95) Gross margin percentage 53.5% SG&A expense 1,191 11% (33) Interest income (87) (1%) 703 Exchange loss/(gain) (89) (1%) (349) ------- -------- ------- 1,015 9% 321 ------- -------- ------- Pretax result 4,805 44% (416) ======= ======== ======= R&D SYSTEMS EUROPE (in thousands of $'s) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ------------------ ------------------- First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 17,838 100% (1,103) Cost of sales 8,295 47% 364 ------- -------- ------- Gross margin 9,543 53% (1,467) Gross margin percentage 53.5% SG&A expense 1,952 11% (331) Interest income (143) (1%) 1,328 Exchange loss/(gain) (145) (1%) (621) ------- -------- ------- 1,664 9% 376 ------- -------- ------- Pretax result 7,879 44% (1,843) ======= ======== ======= HEMATOLOGY (in thousands of $'s) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ------------------ ------------------- First Percent First Quarter Of Sales Quarter ------- -------- ------- Sales 4,668 100% 422 Cost of sales 2,319 50% (50) ------- -------- ------- Gross margin 2,349 50% 472 Gross margin percentage 50.3% SG&A expense 370 8% (66) R&D expense 198 4% 5 Interest, net (72) (2%) 30 ------- -------- ------- 496 10% (31) ------- -------- ------- Pretax result 1,853 40% 503 ======= ======== ======= CORPORATE AND OTHER (2) (in thousands of $'s) Increase (Decrease) Fiscal 2010 From Fiscal 2009 ----------- ------------------- First First Quarter Quarter ------- ------- Interest income 182 (48) Rental income 81 (18) ------- ------- 263 (66) SG&A expense 982 2 Other-Building expenses 548 (5) Other-Equity Investment losses 338 79 ------- ------- 1,868 76 ------- ------- Pretax result (1,605) (142) ======= ======= (2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC and Nephromics, LLC.